Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Mad2 who wrote (1864)	12/8/1999 9:40:00 PM
From: DanZ	Read Replies (1) \| Respond to of 5582

Mad2, I never said that stocks don't make irrational short term moves based on factors that shouldn't affect them. QGLY's stock was obviously negatively affected by the publicity surrounding their problems with the FTC. If GUMM declined in sympathy with Quigley the other day, even though I think that this would have been irrational, then GUMM might have gone up in sympathy with Quigley today. GUMM was up today, but there's no way to tell if it had anything to do with Quigley's press release. Regards, Dan

To: Mad2 who wrote (1864)	12/8/1999 11:01:00 PM
From: Mike M	Respond to of 5582

I see you do subscribe to the "association" between QGLY and Zicam/GUMM, when it suits you(sic) arguement(sic). Mad what is the point of this contentious comment? Nobody ever denied that zinc gluconate was a mutual ingredient. While I don't agree with Dan that there should be a spillover effect for GUMM just because of the QGLY news, he has a right to think it while maintaining there is a distinction between the products. The rest of the comment surely affirms that: <<<...This reafirms what many of us already believe: that zinc reduces the duration and severity of the common cold. Zicam just does it better than Cold Eeze, and that's one reason that Quigley's sales are falling while Gum Tech's are soaring.>>> Cold Eeze has three problems that Zicam doesn't...1) foul taste of zinc lozenge 2) advanced infection denies zinc delivery and undermines efficacy 3)zinc lozenge is easy to duplicate without violating the patent....Furthermore, by going directly to the point of attack for the rhinovirus Zicam is quicker and much more effective... While there are similarities, the differences explain why we "believe" GUMM will not suffer the same fate as Cold Eeze.... You are not required to believe that so what is the point of arguing it further? Neither of us knows the final outcome...Dan and I are making out bets and taking our chances. You can do the same...or, not bet at all.